Primary Care

Dementia

Questions discussed in this category

In older adults with mild cognitive impairment, do you ever prescribe cholinesterase inhibitors and/or memantine?

How do you counsel patients on this off-label use?

7 Answers available

How have the results of the U.S. POINTER study involving multidomain lifestyle interventions to protect cognitive function influenced your practice?

Was the change that was noted in the trial clinically meaningful?Study reference: Baker et al., PMID 40720610

1 Answer available

How do you determine whether to continue anti-dementia medications (such as cholinesterase inhibitors) for patients with dementia when enrolling in hospice?

3 Answers available

What are your thoughts about lion's mane supplementation to slow the decline or improve cognitive capacity for those at risk of dementia?

1 Answer available

What patient factors most strongly influence your decision to start biologic agents in mild cognitive impairment?

Specifically, what guidelines do you use to help determine this (if any)?

1 Answer available

Would you recommend a GLP-1 agonist as an option to reduce the risk of dementia in patients with a strong family history?

As studied in Tang H, Donahoo WT, DeKosky ST, et al. GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related De...

1 Answer available

How do you counsel non-diabetic patients who wish to start metformin to reduce the risk of developing dementia?

2 Answers available

Do you recommend life long aspirin 81 mg daily for non-specific T2 white matter hyper-intensities on MRI brain?

7 Answers available

Papers discussed in this category

Lancet (London, England), 2015 Mar 12

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2018-02

A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia.

JAMA internal medicine, 2025 May 01

Continued Use of Cholinesterase Inhibitors and Memantine in Hospice.

Alzheimer's & dementia (New York, N. Y.), 2022 Jan 31

CCCDTD5 recommendations on the deprescribing of cognitive enhancers in dementia.

The Medical journal of Australia, 2019 Feb 16

Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary.

Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023 Sep 30

Study design and methods: U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER).

JAMA, 2025 Aug 26

Structured vs Self-Guided Multidomain Lifestyle Interventions for Global Cognitive Function: The US POINTER Randomized Clinical Trial.

Related Topics in Primary Care